Article: PDF OnlyBorhani Nemat O.; Brugger, Steven B.; Byington, Robert P.; on behalf of the US MIDAS Research GroupJournal of Cardiovascular Pharmacology: 1990 - p S23-S29 Free Abstract Summary Hypertension is a major risk factor for atherosclerosis. Although antihypertensive drug treatment can re-duce morbidity and mortality from stroke, there is no consistent benefit on ischemic heart disease. It may he that subtle adverse effects of the drugs used in these clinical trials may have blunted the beneficial effects of treatment. Isradipine, a new calcium antagonist of the dihydropyridine class, is a potent antihypertensive drug with pronounced antiatherogenic properties, at least in animal studies. Thus, isradipine may be a suitable drug for assessing the efficacy of antihypertensive treatment in retarding the progression of atherosclerosis. The Multicenter Isradipine/Diuretic Atherosclerosis Study (MIDAS) is a clinical trial to compare the efficacy of isradipine (2.5–5.0 mg h.i.d.) and hydrochlorothiazide (12.5–25 mg h.i.d.) in retarding atherosclerosis in carotid arteries. Carotid atherosclerosis will he monitored using B-mode ultrasonography. The sample size is 800 men and women aged 40 years and over. The power of the design is 90% to detect a 30% difference in the progression of plaque size between the isradipine- and hydrochlorothiazide-treated groups with a significance level of 5% (p = 0.05). Copyright © 1990 Wolters Kluwer Health, Inc. All rights reserved.